<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34749234</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8952</ISSN><JournalIssue CitedMedium="Internet"><Volume>132</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology</Title><ISOAbbreviation>Clin Neurophysiol</ISOAbbreviation></Journal><ArticleTitle>Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan.</ArticleTitle><Pagination><StartPage>3152</StartPage><EndPage>3159</EndPage><MedlinePgn>3152-3159</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinph.2021.09.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1388-2457(21)00759-8</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To determine which compound muscle action potential (CMAP) scan-derived electrophysiological markers are most sensitive for monitoring disease progression in amyotrophic lateral sclerosis (ALS), and whether they hold value for clinical trials.</AbstractText><AbstractText Label="METHODS">We used four independent patient cohorts to assess longitudinal patterns of a comprehensive set of electrophysiological markers including their association with the ALS functional rating scale (ALSFRS-R). Results were translated to trial sample size requirements.</AbstractText><AbstractText Label="RESULTS">In 65 patients, 225 thenar CMAP scan recordings were obtained. Electrophysiological markers showed extensive variation in their longitudinal trajectories. Expressed as standard deviations per month, motor unit number estimation (MUNE) values declined by 0.09 (CI 0.07-0.12), D50, a measure that quantifies CMAP scan discontinuities, declined by 0.09 (CI 0.06-0.13) and maximum CMAP by 0.05 (CI 0.03-0.08). ALSFRS-R declined fastest (0.12, CI 0.08 - 0.15), however the between-patient variability was larger compared to electrophysiological markers, resulting in larger sample sizes. MUNE reduced the sample size by 19.1% (n&#xa0;=&#xa0;388 vs n&#xa0;=&#xa0;314) for a 6-month study compared to the ALSFRS-R.</AbstractText><AbstractText Label="CONCLUSIONS">CMAP scan-derived markers show promise in monitoring disease progression in ALS patients, where MUNE may be its most suitable derivate.</AbstractText><AbstractText Label="SIGNIFICANCE">MUNE may increase clinical trial efficiency compared to clinical endpoints.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 International Federation of Clinical Neurophysiology. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sleutjes</LastName><ForeName>Boudewijn T H M</ForeName><Initials>BTHM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Centre Utrecht, Utrecht, the Netherlands; Department of Neurology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands. Electronic address: b.sleutjes@umcutrecht.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bystrup Jacobsen</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurophysiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tankisi</LastName><ForeName>Hatice</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurophysiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorkem Sirin</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emre Oge</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Royal Brisbane &amp; Women's Hospital, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Doorn</LastName><ForeName>Pieter A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Ruben P A</ForeName><Initials>RPA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Centre Utrecht, Utrecht, the Netherlands; Biostatistics and Research Support, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Clin Neurophysiol</MedlineTA><NlmUniqueID>100883319</NlmUniqueID><ISSNLinking>1388-2457</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="Y">Action Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Compound muscle action potential scan</Keyword><Keyword MajorTopicYN="N">Electrophysiological markers</Keyword><Keyword MajorTopicYN="N">Monitoring disease progression</Keyword><Keyword MajorTopicYN="N">Motor unit number estimation</Keyword><Keyword MajorTopicYN="N">Motor unit sizes</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>8</Day><Hour>20</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34749234</ArticleId><ArticleId IdType="doi">10.1016/j.clinph.2021.09.014</ArticleId><ArticleId IdType="pii">S1388-2457(21)00759-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>